Addition Technology Announces 87% Sales Increase For 2009 Of The Intacs® SK Product Line

Jan. 20, 2010 - PRLog -- Des Plaines, IL, January 13, 2010 – Addition Technology, Inc., the maker of Intacs® corneal implants for the treatment of keratoconus and myopia, and the AlphaCor™ artificial cornea, announced today an 87% increase in Intacs SK sales.  

Despite the challenging 2009 economy, the Intacs® SK treatment for keratoconus, which was launched internationally in 2007, performed strong throughout 2009.  What originated as a concept over 30 years ago continues to succeed as the leading low-risk surgical treatment for keratoconus patients.  Physicians are able to safely treat all grades of keratoconus from mild to the most severe while remaining outside the optical zone.  “With Intacs SK, surgeons can present keratoconus patients with an advanced technology that has a long clinical history (over 13 years) of success”, states William M.  Flynn, President & CEO of Addition Technology Inc.  

Intacs and Intacs SK reshape the cornea with the goal of helping patients achieve functional vision.  One of the most valuable benefits of Intacs is that the product can be exchanged or removed providing a unique comfort level to patients wanting to keep their future eye care options open.   “This product is a world class performer stabilizing many unstable corneas.  Medically, Intacs is the best first option before considering a more invasive corneal transplant for my contact lens intolerant patients,” says Dr. Luis Rodriguez of Venezuela.  The Intacs SK product is now available through the Addition Technology network of global distributors.

Addition Technology, Inc., a privately held eye care company, specializes in novel solutions for sight-threatening eye indications.  Intacs® corneal implants and the AlphaCor™ artificial cornea are patented devices, and the first of their kind, cleared by the FDA and granted CE Mark certification in Europe in addressing vision threatening conditions of the cornea. Intacs® corneal implants are indicated for keratoconus and myopia. AlphaCor™ artificial cornea is indicated as an alternative for high-risk, repeat graft failures. Both products are distributed worldwide.

# # #

Addition Technology, Inc. is a privately held eye care company, specializing in novel solutions for sight-threatening eye indications.